Neonatal BCG immunization followed by dnahsp65 boosters: Highly immunogenic but not protective against tuberculosis-a paradoxical effect of the vector?

Scandinavian Journal of Immunology

Volumn 71, Issue 2, 2010, Pages 63-69

  Pelizon, A C ^a   Martins, D R ^a   Zorzella Pezavento, S F G ^a   Seger, J ^a   Justulin Jr , L A ^a   Da Fonseca, D M ^b   Santos Jr , R R ^b   Masson, A P ^b   Silva, C L ^b   Sartori, A ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 65 ANTIBODY; INTERLEUKIN 5; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL IMMUNITY; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOGENICITY; LUNG HOMOGENATE; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CHAPERONIN 60; CYTOKINES; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; TUBERCULOSIS; VACCINES, DNA;

EID: 75149132604     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02352.x     Document Type: Article

References (38)

1. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001 69: 4195 4201.
2. Rook GA, Hernandez-Pando R. The pathogenesis of tuberculosis. Annu Rev Microbiol 1996 50: 259 284.
3. Andersen P, Doherty TM. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005 3: 656 662.
4. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994 271: 698 702.
5. Springett VH, Sutherland I. A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 1994 75: 227 233. (Pubitemid 2106212)
6. Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999 284: 1520 1523.
7. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995 346: 1339 1345.
8. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006 4: 469 476.
9. McMurray DN. A coordinated strategy for evaluating new vaccines for human and animal tuberculosis. Tuberculosis (Edinb) 2001 81: 141 146.
10. Andersen P. TB vaccines: progress and problems. Trends Immunol 2001 22: 160 168.
11. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996 2: 888 892.
12. Tanghe A, Dsouza S, Rosseels V et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001 69: 3041 3047.
13. Griffin JF, Mackintosh CG, Slobbe L, Thomson AJ, Buchan GS. Vaccine protocols to optimize the protective efficacy of BCG. Tuber Lung Dis 1999 79: 135 143.
14. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001 69: 681 686.
15. Wong YL, Sampson S, Germishuizen WA et al. Drying a tuberculosis vaccine without freezing. Proc Natl Acad Sci USA 2007 104: 2591 2595.
16. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur J Immunol 1996 26: 1489 1496.
17. Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998 66: 169 175.
18. Lowrie DB, Tascon RE, Bonato VL et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999 400: 269 271.
19. Skinner MA, Wedlock DN, de Lisle GW et al. The order of prime-boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins hsp65, hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect Immun 2005 73: 4441 4444.
20. Ramshaw IA, Ramsa AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000 21: 163 165.
21. Majlessi L, Simsova M, Jarvis Z et al. An increase in antimicobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006 74: 2128 2137.
22. Qazi KR, Qazi MR, Julián E, Singh M, Abedi-Valugerdi M, Fernández C. Exposure to mycobacteria primes the immune system for evolutionarily diverse heat shock proteins. Infect Immun 2005 73: 7687 7696.
23. Lagranderie M, Balazuc AM, Abolhassani M et al. Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG. Scand J Immunol 2002 55: 293 303.
24. Ota MO, Vekemans J, Schlegel-Haueter SE et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002 168: 919 925.
25. Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun 1998 66: 5743 5750.
26. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Microbes Infect 2005 7: 962 967.
27. Wong P, Lara-Tejero M, Ploss A, Leiner I, Pamer EG. Rapid development of T cell memory. J Immunol 2004 172: 7239 7245.
28. Rook GA, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol 2004 25: 237 255. (Pubitemid 38296934)
29. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol 2005 5: 318 330.
30. Santos RR Jr., Sartori A, Bonato VL et al. Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression. Clin Exp Immunol 2007 149: 570 578.
31. Santos RR Jr., Sartori A, Lima DS et al. DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes. J Immune Based Ther Vaccines 2009 7: 4.
32. Rook GA, Hernandez-Pando R. Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Novartis Found Symp 1998 217: 73 87.
33. Al-Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guérin (BCG)-vaccinated healthy subjects. Clin Exp Immunol 2009 158: 64 73.
34. Krieg AM. A role for Toll in autoimmunity. Nat Immunol 2002 3: 423 424.
35. Vollmer J, Weeratna RD, Jurk M et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 2004 113: 212 223.
36. Boccaccio GL, Mor F, Steinman L. Non-coding plasmid DNA induces IFN-gamma in vivo and suppresses autoimmune encephalomyelitis. Int Immunol 1999 11: 289 296.
37. Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000 165: 6148 6155.
38. Zorzella-Pezavento SFG, Chiuso-Minicucci F, França TGD et al. Immunization with pVAXhsp65 decreases inflammation and modulates immune response in experimental encephalomyelitis. Neuroimmunomodulation in press).